Myopia Assessment of Two Manufacturing Processes — MAPLE

Juvenile Myopia Clinical Trial

Official title:
Myopia Assessment of Two Manufacturing Processes for Myopia Management Lenses (MAPLE)

Status Completed

Clinical Trial Summary

Randomized, controlled, multisite, subject- and observer-masked, contralateral clinical trial of 6-month duration to compare two SightGlass Vision Diffusion Optics Technology (DOT) spectacle lens manufacturing processes in reducing the progression of juvenile myopia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04126057
Study type	Interventional
Source	SightGlass Vision, Inc.
Contact
Status	Completed
Phase	N/A
Start date	December 2, 2019
Completion date	September 16, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06034327` - Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens	N/A
Active, not recruiting	`NCT05893979` - Myopia Control Spectacle Lens Cessation Study	N/A
Active, not recruiting	`NCT04947735` - CYPRESS Efficacy and Safety Study Extension	N/A
Active, not recruiting	`NCT03623074` - Control of Myopia Using Novel Spectacle Lens Designs	N/A
Active, not recruiting	`NCT05617794` - Effect of Diffusion Optics Technology (DOT) Spectacle Lenses on Choroidal Thickness	N/A
Active, not recruiting	`NCT05562622` - Assessment of DOT Spectacles in Chinese Children	N/A
Completed	`NCT05650190` - Spectacle Lens Visual Acuity Assessments Study	N/A